Painful peripheral neuropathy is a severe and difficult-totreat neurological complication associated with cancer chemotherapy. Although chemotherapeutic drugs such as paclitaxel are known to cause tonic activation of presynaptic NMDA receptors (NMDARs) to potentiate nociceptive input, the molecular mechanism involved in this effect is unclear. a2d-1, commonly known as a voltage-activated calcium channel subunit, is a newly discovered NMDAR-interacting protein and plays a critical role in NMDAR-mediated synaptic plasticity. Here we show that paclitaxel treatment in rats increases the a2d-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord. Paclitaxel treatment also potentiates the a2d-1-NMDAR interaction and synaptic trafficking in the spinal cord. Strikingly, inhibiting a2d-1 trafficking with pregabalin, disrupting the a2d-1-NMDAR interaction with an a2d-1 C-terminus-interfering peptide, or a2d-1 genetic ablation fully reverses paclitaxel treatment-induced presynaptic NMDAR-mediated glutamate release from primary afferent terminals to spinal dorsal horn neurons. In addition, intrathecal injection of pregabalin or a2d-1 C-terminus-interfering peptide and a2d-1 knockout in mice markedly attenuate paclitaxel-induced pain hypersensitivity. Our findings indicate that a2d-1 is required for paclitaxel-induced tonic activation of presynaptic NMDARs at the spinal cord level. Targeting a2d-1-bound NMDARs, not the physiological a2d-1-free NMDARs, may be a new strategy for treating chemotherapy-induced neuropathic pain.
Painful peripheral neuropathy is a major adverse effect of several chemotherapeutic agents used for treating cancer, including taxanes, bortezomib, platinum agents, and vinca alkaloids. The persistent pain caused by chemotherapy profoundly reduces patients' quality of life and is often the reason for dose reduction or discontinuation of what is otherwise life-saving treatment (Grisold et al. 2012; Sisignano et al. 2014) . Because chemotherapy-induced pain responds poorly to conventional analgesics, identifying its molecular determinants is critically important for the development of new mechanism-based therapies. Glutamate mediates the vast majority of fast excitatory synaptic transmissions in the central nervous system, and the glutamate N-methyl-D-aspartate receptor (NMDAR) is involved in many physiological functions, such as learning, memory, and the synaptic plasticity associated with chronic pain (Herron et al. 1986; Weisskopf and Nicoll 1995; Chaplan et al. 1997; Zhou et al. 2012; Chen et al. 2014b) . Although conventional NMDARs are located postsynaptically, presynaptic NMDARs can also powerfully shape synaptic transmission and neuronal plasticity in the amygdala (Humeau et al. 2003) , striatum (Park et al. 2014) , hypothalamus (Ye et al. 2011) , and hippocampus (McGuinness et al. 2010) . NMDARs are present in primary sensory neurons and their the central terminals (Liu et al. 1994; McRoberts et al. 2011 ), but they are normally silent in the spinal dorsal horn (Zeng et al. 2006; Zhao et al. 2012; Li et al. 2016; Xie et al. 2016) . Interestingly, both treatment with paclitaxel, a microtubule-stabilizing agent, and treatment with bortezomib, a proteasome inhibitor, have no effect on postsynaptic NMDAR activity but lead to tonic activation of presynaptic NMDARs in the spinal dorsal horn (Chen et al. 2014c; Xie et al. 2016 Xie et al. , 2017 . However, the molecular mechanism responsible for this chemotherapy-induced presynaptic NMDAR activation remains unclear.
a2d-1 is commonly known as a subunit of voltage-activated calcium channels (VACCs) (Dolphin 2013 ). However, quantitative proteomic analysis shows that a2d-1 has a weak interaction with VACC a1 subunits in the brain tissues (Muller et al. 2010) , and VACC currents in brain neurons are similar in wild-type and a2d-1 knockout mice (Felsted et al. 2017) . a2d-1 is a major binding site of gabapentinoids, including gabapentin and pregabalin (Gee et al. 1996; Field et al. 2006; Fuller-Bicer et al. 2009 ), which are used for treating patients with chronic pain, including chemotherapyinduced neuropathic pain (Tsavaris et al. 2008; Finnerup et al. 2015) . But gabapentinoids have little effect on VACC, including N-type, currents (Rock et al. 1993; Schumacher et al. 1998; Chen et al. 2018) or VACC-mediated neurotransmitter release (Brown and Randall 2005; Hoppa et al. 2012) . Thus, the relevant mechanism responsible for the therapeutic action of these drugs is uncertain. We showed recently that a2d-1 can form a protein complex with NMDARs to regulate NMDAR activity in traumatic nerve injury-induced chronic pain . Nevertheless, chronic pain caused by chemotherapy involves different cellular and molecular mechanisms from those involved in chronic pain caused by traumatic nerve injury. For example, spinal nerve ligation impairs K + -Cl À cotransporter-2 (KCC2) activity (Zhou et al. 2012) , whereas paclitaxel increases Na
À cotransporter-1 (NKCC1) activity, in the spinal dorsal horn (Chen et al. 2014c) . Furthermore, spinal nerve ligation potentiates both presynaptic and postsynaptic NMDAR activity (Chen et al. 2014b; Li et al. 2016) , whereas treatment with paclitaxel or bortezomib increases presynaptic, but not postsynaptic, NMDAR activity in the spinal cord (Chen et al. 2014c; Xie et al. 2016 Xie et al. , 2017 . Currently, little is known about the contribution of a2d-1 to chemotherapyinduced tonic activation of presynaptic NMDARs. The purpose of the present study was to determine the role of a2d-1-NMDAR interaction in the potentiated synaptic glutamate release to dorsal horn neurons in paclitaxel-induced neuropathic pain. Our study shows for the first time that a switch from a2d-1-free to a2d-1-bound NMDARs is essential in paclitaxel-induced tonic activation of presynaptic NMDARs. This new information substantially extends our understanding of the molecular mechanism underlying chemotherapy-induced neuropathic pain and the therapeutic actions of gabapentinoids. Our findings also suggest that targeting the a2d-1-NMDAR interaction site represents a new strategy for treating chemotherapy-induced chronic pain.
Materials and methods

Animals and paclitaxel treatment
All surgical procedures and experimental protocols were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center (approval #1174-RN01) and complied with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. This study was not pre-registered. Adult male Sprague-Dawley rats (weight: 220-250 g; Harlan, Indianapolis, IN, USA; RRID: RGD_5508397) were used for most experiments. All animals were housed (2-3 rats per cage) on a standard 12 : 12 light-dark cycle with normal illumination. They were housed with three animals per cage and had free access to food and water. All tests and assays were done between 9 am and 6 pm.
Generation of a2d-1 À/À (KO) mice has been described previously (Fuller-Bicer et al. 2009 ). Briefly, two breeding pairs of a2d-1 +/À mice (C57BL/6 genetic background) were purchased from Medical Research Council (Stock #6900; Harwell Didcot, Oxfordshire, UK). a2d-1 À/À and a2d-1 +/+ (WT) littermates were generated by breeding the a2d-1 +/À heterozygous mice. Animals were ear-marked at the time of weaning (3 weeks after birth), and tail biopsies were used for PCR genotyping. Both male and female adult mice were used for electrophysiological and behavioral experiments. Because we observed no differences in electrophysiological and behavioral data between male and female mice, these data were pooled.
To induce neuropathic pain, we intraperitoneally injected rats and mice with paclitaxel (2 mg/kg; TEVA Pharmaceuticals, North Wales, PA, USA) every 2 days for a total of 4 injections (days 1, 3, 5, and 7; total dose, 8 mg/kg), as described previously (Polomano et al. 2001) . Animals in the control group were intraperitoneally injected with the vehicle (Cremophor EL/ethanol, 1 : 1) on the same 4 days. The presence of tactile allodynia was confirmed 10-12 days after drug treatment. We implanted intrathecal catheters in some paclitaxel-treated rats during isoflurane-induced anesthesia. Briefly, we made a small puncture in the atlanto-occipital membrane of the cisterna magna and inserted a PE-10 catheter with the caudal tip reaching the lumbar enlargement of the spinal cord. To minimize animal's suffering, 1% lidocaine was injected around the incision site during surgery. We allowed the animals to recover for at least 4 days before intrathecal injections. Rats displaying signs of motor or neurological dysfunction were immediately killed with an intraperitoneal injection of phenobarbital (200 mg/kg) or by CO 2 inhalation. All final biochemical and electrophysiological recordings were performed 14-20 days after paclitaxel or vehicle injection.
Quantitative PCR Rats were deeply anesthetized with 5% isoflurane, and the dorsal root ganglion (DRG) and dorsal half of spinal cord tissues at the L5 and L6 levels were removed. Total RNA was extracted from the DRG and spinal cord tissues using TRIsure (#BIO-38032, Bioline, Taunton, MA, USA). After treatment with RNase-free DNase (#79254, QIAGEN, Hilden, Germany), 500 ng RNA was used for reverse transcription with a RevertAid RT Reverse Transcription Kit (#K1619, Thermo Fisher Scientific, Waltham, MA, USA). One lL of five times diluted cDNA was added to a 10-lL reaction volume with SYBR Green Real-Time PCR Mix (#A25780, Thermo Fisher Scientific). Real-time PCR was performed using a QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). The thermal cycling conditions used were: 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for 60 s. The following primers were used: a2d-1 forward, GGACCTATTCAGT GGATGGCTTG; a2d-1 reverse, CCATTGGTCTTCCCAGAACA TCTAGA; a2d-2 forward, CGGCTGCTACAAAAGGAGACAC ACT; a2d-2 reverse, CGGCCACAGTCTGAGGTATCTTC; a2d-3 forward, GGCTCAGAAGATCAGACGACGTC; a2d-3 reverse, TTGAGAAGAGACTCGAAACCAGG; Gapdh forward, GACAT GCCGCCTGGAGAAAC; Gapdh reverse, AGCCCAGGATGCC CTTTAGT; GluN1 forward, GGATAAGACATGGGTTCGGTAT CAGG; GluN1 reverse, TGTGTCGCTTGTAGGCGATCTC; GluN2A forward, TCAGCCATTGCTGTCTTCGT; GluN2A reverse, TGATCTTGCTGGTTGTGCCT; GluN2B forward, TTTCTAGC GCAGAAGGGCTC; GluN2B reverse, ATGGCCTTCCTCAGAA CACC. Relative mRNA levels were calculated using the 2 ÀDDCT method and normalized to the Gapdh level in the same sample.
Coimmunoprecipitation using spinal cord tissue membrane extracts Tissues from the dorsal halves of the rat spinal cord at the L5 and L6 levels were collected under isoflurane anesthesia and homogenized in ice-cold hypotonic buffer (20 mM Tris [pH 7.4], 1 mM CaCl 2 , 1 mM MgCl 2 , and protease inhibitors) for extracting membrane proteins. The nuclei and unbroken cells were removed by centrifugation at 300 g for 5 min, and the supernatant was centrifuged for 20 min at 21 000 g. The pellets were re-suspended and solubilized in immunoprecipitation buffer (50 mM Tris [pH7.4], 250 mM NaCl, 10% glycerol, 0.5% NP-40, 20 mM NaF, 1 mM Na 3 VO 4 , 10 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, 2 mM benzamide, and protease inhibitors), and the soluble fraction was incubated at 4°C overnight with Protein A/G beads (#16-266, Millipore, Darmstadt, Germany) prebound to mouse anti-GluN1 antibody (#75-272, 1 : 1000, NeuroMab, Davis, CA, USA; RRID: AB_11000180). Protein A/G beads prebound to mouse IgG were uses as the control. All samples were washed three times with immunoprecipitation buffer and then immunoblotted with rabbit anti-a2d-1 (#ACC-015, 1 : 500, Alomone Labs, Jerusalem, Israel; RRID: AB_2039785) and rabbit anti-GluN1 antibodies (#G8913, 1 : 1000, Sigma-Aldrich, St. Louis, MO, USA; RRID: AB_259978). The amount of the a2d-1-GluN1 protein complex was calculated by normalizing the amount of a2d-1 to that of GluN1 on the same gel.
Spinal cord synaptosome preparation
The tissues from the dorsal half of the rat spinal cords were homogenized using a glass-Teflon homogenizer in 10 volumes of ice-cold HEPES-buffered sucrose (0.32 M sucrose, 1 mM EGTA, and 4 mM HEPES at pH 7.4) containing a protease inhibitor cocktail (Sigma-Aldrich). The homogenate was centrifuged at 1000 g for 10 min at 4°C to remove the sediment, including nuclei and large debris. Then the supernatant was centrifuged at 10 000 g for 15 min to obtain the crude synaptosomal fraction. The synaptosomal pellet was lysed in 9 volumes of ice-cold HEPES-buffer with the protease inhibitor cocktail for 30 min. The lysate was centrifuged at 25 000 g for 20 min at 4°C to obtain the synaptosomal fraction . After the protein concentration was measured, 30 lg of proteins were used for western immunoblotting. The amount of synaptic a2d-1 and GluN1 proteins was normalized to that of PSD-95, a synaptic protein marker, on the same gel (see below).
Western immunoblotting
The rat DRG and dorsal spinal cord tissues at L5-L6 levels were homogenized in 300 lL radioimmunoprecipitation assay buffer containing 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , and 1 mM NaF in the presence of a proteinase inhibitor cocktail (Sigma-Aldrich). The samples were homogenized with lysis buffer on ice for 30 min, and centrifuged at 13 000 g for 30 min at 4°C. The supernatant was collected, and its protein concentration was measured using a DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Thirty micrograms of protein was loaded and separated by 4-15% Tris-HCl sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (#456-1086, Bio-Rad, Hercules, CA, USA). The resolved proteins were transferred to a polyvinylidene difluoride membrane. The membrane was treated with 5% non-fat dry milk in Tris-buffered saline at 25°C for 1 h and then incubated in Tris-buffered saline supplemented with 0.1% Triton X-100, 1% bovine serum albumin, and rabbit anti-a2d-1 (#ACC-015, 1 : 500, Alomone Labs, Jerusalem, Israel), rabbit anti-GluN1 (#G8913, 1 : 1000, Sigma-Aldrich), rabbit anti-GAPDH (#14C10, 1 : 5000, Cell Signaling Technology, Danvers, MA, USA), or mouse anti-PSD95 (#75-348, 1 : 1000, NeuroMab, Davis, CA, USA) antibodies overnight at 4°C. The membrane was washed three times and then incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1 : 5000; Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at 25°C. The protein bands were detected with an ECL kit (Thermo Fisher Scientific), and protein band intensity was visualized and quantified using an Odyssey Fc Imager (LI-COR Biosciences, Lincoln, NE, USA).
Electrophysiological recording in spinal cord slices
We anesthetized the rats and mice with isoflurane and rapidly removed the L3-L6 level of the lumbar spinal cord through laminectomy. The spinal cord tissues were immediately placed in ice-cold sucrose artificial cerebrospinal fluid (containing 234 mM sucrose, 3.6 mM KCl, 1.2 mM NaH 2 PO 4 , 12.2 mM glucose, 25.0 mM NaHCO 3, 1.2 mM MgCl 2 , and 2.5 mM CaCl 2 ) presaturated with 95% O 2 and 5% CO 2 . Then the spinal cord tissue was placed onto the stage of a vibratome (Leica, Buffalo Grove, NY, USA) and sliced transversely into 400 lm sections, which were preincubated in Krebs solution (117.0 mM NaCl, 3.6 mM KCl, 1.2 mM NaH 2 PO 4 , 11.0 mM glucose, 25.0 mM NaHCO 3 , 1.2 mM MgCl 2 , and 2.5 mM CaCl 2 ) oxygenated with 95% O 2 and 5% CO 2 at 34°C for at least 1 h before being transferred to recording chamber. The spinal cord slices were placed in a glass-bottomed recording chamber and continuously perfused with Krebs solution at 5.0 mL/min at 34°C, maintained by an inline solution heater and a temperature controller.
The lamina II outer neurons were identified for recording because they are mostly glutamate-releasing excitatory neurons and involved in nociceptive transmission Santos et al. 2007; Wang et al. 2018) . Excitatory postsynaptic currents (EPSCs) were recorded using whole-cell voltage-clamp techniques. The impedance of the glass electrode was 4-7 MΩ when the pipette was filled with the internal solution containing 135 mM potassium gluconate, 5 mM KCl, 2.0 mM MgCl 2 , 0.5 mM CaCl 2 , 5.0 mM HEPES, 5.0 mM EGTA, 5.0 mM ATP-Mg, 0.5 mM Na-GTP, and 10 mM lidocaine N-ethyl bromide (QX314, 280-300 mOsm, pH: 7.25). To measure glutamate release from primary afferent nerves, EPSCs were evoked from the dorsal root using a bipolar tungsten electrode connected to a stimulator (0.5 ms, 0.6 mA, and 0.1 Hz) and were recorded at a holding potential of À60 mV. Monosynaptic EPSCs were identified on the basis of the constant latency and absence of conduction failure of evoked EPSCs in response to a 20-Hz electrical stimulation. We have shown that bath application of an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist can abolish all evoked monosynaptic EPSCs (elicited by glutamate release) in our preparation Pan et al. 2002) and that manipulating primary afferent nerves predictably alters glutamatergic input to lamina II neurons (Zhou et al. 2008 (Zhou et al. , 2010 .
The paired-pulse ratio (PPR) was evoked by a pair of stimuli given at 50-ms intervals; the PPR was defined as the ratio of the amplitude of the second synaptic response to the amplitude of the first synaptic response. Miniature EPSCs (mEPSCs) were recorded at a holding potential of -60 mV in the presence of 2 lM strychnine, 10 lM bicuculline, and 1 lM tetrodotoxin. The input resistance was monitored, and the recording was abandoned if the input resistance changed by more than 15%. All signals were recorded using an amplifier (MultiClamp 700B; Axon Instruments Inc., Union City, CA, USA), filtered at 1-2 kHz, and digitized at 10 kHz.
All drugs were prepared in artificial cerebrospinal fluid before the recording and delivered via syringe pumps at their final concentrations. 2-Amino-5-phosphonopentanoic acid (AP5) and tetrodotoxin citrate were purchased from Hello Bio Inc. (Princeton, NJ, USA). Pregabalin was obtained from Tocris Bioscience (Bristol, UK). A peptide mimicking the C-terminal domain (VSGLNPSLWSIFGLQF ILLWLVSGSRHYLW) of a2d-1 fused with Tat protein (YGRKK RRQRRR) and a scrambled control peptide (FGLGWQPWSLSF YLVWSGLILSVLHLIRSN) fused with Tat were synthesized by Bio Basic Inc. (Marham, Ontario, Canada). Pregabalin, a2d-1Tat peptide, and control peptide were dissolved in artificial cerebrospinal fluid immediately before use.
Behavioral assessment of nociception
To measure tactile allodynia, mice or rats were individually placed on a mesh floor within a suspended chamber. We applied a series of calibrated von Frey filaments (Stoelting, Wood Dale, IL, USA) perpendicularly to the plantar surface of both hindpaws with sufficient force to bend the filament for 6 s. Brisk withdrawal of the paw or flinching was considered a positive response. When a response was observed, we applied the filament of the next lower force. In the absence of a response, we applied the filament of the next greater force. We used the 'up-down' method (Chaplan et al. 1994) to calculate the tactile stimulus that produced a 50% likelihood of a withdrawal response.
To quantify the mechanical nociceptive threshold in rats, we conducted the paw pressure (Randall-Selitto) test on the left hindpaw using an analgesiometer (Ugo Basile, Varese, Italy). To activate the device, we pressed a foot pedal, which then applied a constantly increasing force on a linear scale. When the rat withdrew its paw or vocalized, the pedal was immediately released, and the withdrawal threshold was recorded (Chen et al. 2014a ). We did not conduct the paw pressure test in mice because it is difficult to determine the mouse's hindpaw withdrawal threshold using this analgesiometer.
To assess the thermal sensitivity of rats, we placed them individually on the glass surface of a thermal testing apparatus (IITC Life Sciences, Woodland Hills, CA, USA). The rats were allowed to acclimate for 30 min before testing. The temperature of the glass surface was maintained at a constant 30°C. A mobile radiant heat source located under the glass was focused onto the hindpaw of each rat (Chen and Pan 2006) . The paw withdrawal latency was recorded with a timer, and the hindpaw was tested twice to obtain an average time.
An incremental hot/cold plate analgesia meter (IITC Life Sciences) was used to determine the thermal sensitivity of mice. Mice were placed individually in the observation chamber on the plate, which had been preheated to 30°C for 60 min. To measure heat sensitivity, the plate was heated at a rate of 6°C/min until the mice showed nocifensive behaviors such as paw shaking and jumping (Laumet et al. 2015) . After the threshold temperature was recorded, the mice were immediately removed from the plate. The heat threshold measurement was repeated 30 min later, and the average of the two recorded temperatures was considered as the heat threshold. The cold threshold was measured by cooling the plate from 30°C at a rate of 6°C/min until nocifensive behaviors were observed. The investigators performing the behavioral experiments were blinded to the treatment.
Study design and statistical analysis
The timeline of experimental procedures is shown in Fig. 1 . Although no statistical methods were used to predetermine sample sizes for the studies, our sample sizes were similar to those generally employed in the field. The animals were assigned (1 : 1 allocation) to the control and treatment groups, and no randomization methods were used. We did not exclude any animals from data analysis and did not use any test for outliers on the data. For electrophysiological experiments, at least three animals were used for each recording protocol, and only one neuron was recorded from each spinal cord slice. The amplitude of evoked EPSCs was quantified by averaging 10 consecutive EPSCs measured using Clampfit 10.0 software (Axon Instruments). mEPSCs were analyzed off-line using the peak detection program (MiniAnalysis, Synaptosoft, Leonia, NJ, USA). We monitored cell capacitance, input resistance, and baseline holding current; the recording was discontinued if these parameters changed > 15%. D'Agostino-Pearson normality test was used to assess the normality of data. The biochemical and electrophysiological data were presented in box-whisker plots, which show the minimum, 25th percentile, median, 75th percentile, and maximum. Two-tailed Student's t-tests were used to compare two groups, and one-way analysis of the variance (ANOVA) followed by Dunnett's or Tukey's post hoc test was used to determine the differences between more than two groups. Two-way ANOVA followed by Tukey's post hoc test was performed to compare the withdrawal thresholds in WT mice and KO mice. All statistical analyses were performed using Prism software (version 7, GraphPad Software Inc., La Jolla, CA, USA). P values of less than 0.05 were considered to indicate statistically significant differences. Fig. 1 Flowchart diagrams show the timeline of experimental procedures used in the study. Rats were treated with either paclitaxel or vehicle (top panels) and then used for behavioral, biochemical, or electrophysiological experiments. Wild-type and a2d-1 knockout mice were treated with paclitaxel or vehicle (lower panels), and nociceptive tests or electrophysiological recordings were performed at the time indicated. DRG, dorsal root ganglion; SC, spinal cord; WB, Western blotting. The number of animals used for each group was indicated in parenthesis. Fig. 2 Paclitaxel increases a2d-1 expression levels and synaptic trafficking of a2d-1-bound N-methyl-D-aspartate receptors (NMDARs) in the spinal cord. (a-c) Original gel images (a and b, two pairs of samples) and quantification (c) of the a2d-1 protein level in the DRG and dorsal spinal cord tissues of paclitaxel-treated (P) and vehicletreated (V) rats (n = 9 rats per group). The amount of a2d-1 proteins was normalized to that of GAPDH on the same blot. (d-f) Quantification of the mRNA level of a2d-1, a2d-2, a2d-3, GluN1, GluN2A, and GluN2B in the DRG and dorsal spinal cord tissues of paclitaxeltreated (P) and vehicle-treated (V) rats (n = 6 rats per group). (g and h) co-IP analysis showing the interaction between a2d-1 and GluN1 in the membrane extracts of dorsal spinal cord tissues from rats treated with paclitaxel (P) or vehicle (V) (n = 6 rats per group).
Proteins were immunoprecipitated initially with a mouse anti-GluN1 or anti-IgG antibody. Immunoblotting was performed by using rabbit antia2d-1 and anti-GluN1 antibodies. The amount of a2d-1 proteins was normalized to that of GluN1 on the same blot. (i and j) Representative gel images (i, three pairs of samples) and quantification (j) of the protein levels of a2d-1, GluN1, and PSD-95 (a synaptic marker) in synaptosomes isolated from dorsal spinal cord tissues of paclitaxeltreated (P) and vehicle-treated (V) rats (n = 8 rats per group). The amount of a2d-1 and GluN1 proteins was normalized to that of PSD-95 on the same blot. Values in C-F, H, and J are normalized to expression levels in vehicle-treated rats. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the vehicle-treated group (paired Student's t-test).
Results
Paclitaxel treatment increases a2d-1 protein and mRNA levels in the DRG and spinal cord a2d-1 is expressed in DRG neurons and primary afferent nerve terminals in the superficial dorsal horn of the spinal cord. Peripheral nerve injury causes a large increase in the a2d-1 expression level in the DRG and spinal cord (Luo et al. 2001; Newton et al. 2001) . We used western immunoblotting and real-time PCR to determine whether paclitaxel treatment affects the a2d-1 expression level in the DRG and dorsal spinal cord tissues of rats. Immunoblotting detected a protein band corresponding to the molecular mass of a2d-1 (~140 kDa). The a2d-1 protein levels in the DRG (p = 0.0022, t(8) = 4.43; n = 9 rats in each group) and spinal cord tissues (p = 0.026, t(8) = 2.73; n = 9 rats in each group) were significantly higher in paclitaxel-treated than in vehicle-treated rats (Fig. 2a-c) .
Real-time PCR analysis showed that the a2d-1 mRNA levels in the DRG (p = 0.0039, t(10) = 3.73; n = 6 rats in each group) and dorsal spinal cord (p = 0.0031, t(10) = 3.89; n = 6 rats in each group) were significantly higher in paclitaxel-treated than in vehicle-treated rats (Fig 2d) . However, the mRNA level of a2d-2 or a2d-3 in the DRG and dorsal spinal cord was similar in paclitaxel-treated and vehicle-treated rats (n = 6 rats in each group, Fig. 2e) . Furthermore, the mRNA levels of GluN1, GluN2A, and GluN2B in the dorsal spinal cord were significantly higher in paclitaxel-treated than in vehicle-treated rats (n = 6 rats in each group, Fig 2f) . But in the DRG, only the mRNA level of GluN2B was significantly higher in paclitaxel-treated than in vehicle-treated rats (n = 6 rats in each group, Fig. 2f ). These results indicate that paclitaxel treatment increases the expression of a2d-1 in the DRG and spinal cord and NMDAR expression level in the spinal cord.
Paclitaxel treatment increases the interaction between a2d-1 and NMDARs and the synaptic targeting of NMDARs in the spinal cord Coimmunoprecipitation (co-IP) was performed to determine whether paclitaxel treatment affects the interaction of a2d-1 and GluN1 (an obligatory subunit of NMDARs) in the dorsal spinal cord. Co-IP assays showed that a mouse anti-GluN1 antibody, but not an irrelevant mouse anti-immunoglobulin G (anti-IgG) antibody, coprecipitated with a2d-1 in spinal cord membrane extracts (Fig. 2g) . In addition, the expression level of the a2d-1-GluN1 complex in the dorsal spinal cord was significantly higher in paclitaxel-treated than in vehicletreated rats (p = 0.0197, t(10) = 2.77; n = 6 rats in each group; Fig. 2g and h ).
To determine whether paclitaxel treatment increases synaptic trafficking of NMDARs, we quantified a2d-1 and GluN1 proteins in synaptosomes isolated from dorsal spinal cord tissues. Immunoblotting showed that both a2d-1 and GluN1 protein levels in spinal synaptosomes were significantly higher in paclitaxel-treated than in vehicle-treated rats (n = 8 rats in each group; Fig. 2i and j) . These data suggest that paclitaxel treatment promotes the a2d-1-GluN1 interaction and the synaptic trafficking of a2d-1-bound NMDARs at the spinal cord level.
a2d-1 mediates paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn Chemotherapy-induced neuropathic pain is associated with tonic activation of presynaptic NMDARs, which promotes nociceptive glutamatergic input to spinal dorsal horn neurons (Xie et al. , 2017 . To determine the contribution of a2d-1 to the increase in presynaptic NMDAR activity caused by paclitaxel treatment, we examined the effect of pregabalin, a clinically used a2d-1 inhibitory ligand Patel et al. 2013) , on glutamatergic miniature excitatory postsynaptic currents (mEPSCs), which represent spontaneous quantal glutamate release from presynaptic terminals of spinal dorsal horn neurons. Both gabapentin and pregabalin can inhibit synaptic trafficking and activity of a2d-1-bound NMDARs Ma et al. 2018) . The baseline frequency, but not the amplitude, of mEPSCs in lamina II neurons was significantly higher in paclitaxeltreated rats than in vehicle-treated rats (5.48 AE 0.52 Hz vs. 3.86 AE 0.43 Hz, p = 0.028; n = 12 neurons in each group; Fig. 3 ). Bath application of the specific NMDAR antagonist 2-amino-5-phosphonopentanoate (AP5, 50 lM) rapidly reversed the increase in the frequency of mEPSCs in paclitaxel-treated rats but had no effect in vehicle-treated rats (Fig. 3) , confirming that presynaptic NMDARs in the spinal dorsal horn are tonically activated by paclitaxel traces and cumulative plots (c) and box-and-whisker plots (d) show the effect of bath application of AP5 on the frequency and amplitude of mEPSCs of lamina II neurons from vehicle-treated rats. Neurons were treated with 20 lM pregabalin (+pregabalin, n = 10 neurons from four rats) or untreated (-pregabalin, n = 12 neurons from four rats). *p < 0.05 compared with the respective baseline control (one-way ANOVA followed by Dunnett's post hoc test).
# p < 0.05 compared with the baseline level in the group without pregabalin treatment (one-way ANOVA followed by Tukey's post hoc test).
treatment . Treatment with pregabalin (20 lM for 30-60 min) completely normalized the baseline frequency of mEPSCs of lamina II neurons, which had been increased by paclitaxel treatment (n = 10 neurons, Fig. 3a and b). In these pregabalin-treated neurons from paclitaxeltreated rats, subsequent bath application of 50 lM AP5 no longer had any effect on the frequency of mEPSCs. In contrast, pregabalin had no effect on the baseline frequency of mEPSCs in lamina II neurons from vehicle-treated rats (n = 10 neurons; Fig. 3c and d) . These data suggest that a2d-1 mediates paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal cord.
a2d-1 is critical for paclitaxel-induced activation of NMDARs at primary afferent terminals NMDARs are expressed at primary afferent terminals in the superficial dorsal horn of the spinal cord (Liu et al. 1994) , where they mediate chemotherapy-induced potentiation of glutamatergic input to the spinal dorsal horn (Xie et al. , 2017 . To determine the role of a2d-1 in the increased activity of NMDARs at primary afferent terminals caused by paclitaxel treatment, we recorded EPSCs of lamina II neurons monosynaptically evoked from the dorsal root, which correspond to synaptic glutamate release elicited from primary afferent nerve terminals. The baseline amplitude of evoked monosynaptic EPSCs was significantly larger in paclitaxel-treated rats (n = 12 neurons) than in vehicle-treated rats (516.83 AE 34.16 pA vs. 408.25 AE 25.49 pA, p = 0.031; n = 8 neurons) (Fig. 4) . Bath application of 50 lM AP5 rapidly reversed the increased amplitude of monosynaptic EPSCs of lamina II neurons from paclitaxel-treated rats but had no effect in vehicle-treated rats (Fig. 4) . In spinal cord slices from paclitaxel-treated rats, treatment with 20 lM pregabalin for 30-60 min returned the amplitude of evoked monosynaptic EPSCs of lamina II neurons to the baseline level observed in vehicle-treated rats (n = 8 neurons, Fig. 4a and b) . However, pregabalin treatment had no effect on the amplitude of evoked monosynaptic EPSCs of lamina II neurons from vehicletreated rats (n = 9 neurons, Fig. 4c and d) .
In addition, we determined the effect of pregabalin on the PPR, a commonly used measure of the probability of neurotransmitter release from the presynaptic neuron, of monosynaptically evoked EPSCs of spinal lamina II neurons. Paclitaxel treatment significantly reduced the PPR in lamina II neurons (n = 9) compared with that in neurons (n = 8) from vehicle-treated rats (0.53 AE 0.04 vs. 0.78 AE 0.06, p = 0.028; Fig. 4e and f) . Bath application of AP5 reversed the reduction in the PPR of lamina II neurons from paclitaxel-treated rats but had no effect on the PPR in neurons from vehicle-treated rats ( Fig. 4e and  f) . Treatment with pregabalin completely normalized the PPR that had been reduced by paclitaxel treatment (n = 8 neurons) but had no effect on the PPR in neurons from vehicle-treated rats (n = 9 neurons) ( Fig. 4e and f) . These results suggest that a2d-1 is critically involved in paclitaxel-induced activation of NMDARs at primary afferent terminals.
a2d-1-bound NMDARs are essential for paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn We next determined whether the a2d-1-NMDAR interaction is involved in the paclitaxel-induced activation of presynaptic NMDARs in the spinal dorsal horn. Because the C-terminus of a2d-1 is essential for its interaction with NMDARs, we developed a 30-amino-acid peptide (VSGLNPSLWSIFGLQ-FILLWLVSGSRHYLW) mimicking the C-terminal domain of a2d-1 fused with Tat protein (YGRKKRRQRRR) termed as a2d-1Tat peptide. We have shown that a2d-1Tat peptide effectively disrupts the a2d-1-NMDAR interaction in vitro and in vivo Luo et al. 2018) . Treatment with this a2d-1Tat peptide (1 lM for 30-60 min) completely normalized the increased baseline frequency of mEPSCs in lamina II neurons from paclitaxel-treated rats (n = 10 neurons) to the level seen in vehicle-treated rats ( Fig. 5a  and b) . Subsequent bath application of AP5 had no effect on the frequency of mEPSCs in a2d-1Tat peptide-treated spinal cord slices from paclitaxel-treated rats. However, in spinal cord slices from vehicle-treated rats, neither incubation with a2d-1Tat peptide nor bath application of AP5 had any effect on the baseline frequency of mEPSCs in lamina II neurons (n = 11 neurons; Fig. 5c and d) .
In contrast, treatment with a Tat-fused scrambled control peptide (FGLGWQPWSLSFYLVWSGLILSVLHLIRSN; 1 lM for 30-60 min) did not affect the mEPSC frequency of lamina II neurons from paclitaxel-treated rats (n = 11 Original recording traces (e) and box-and-whisker plots (f) shows the effect of bath application of AP5 on the paired-pulse ratio (PPR) of lamina II neurons treated with pregabalin (+pregabalin) and of untreated neurons (-pregabalin) from vehicle-treated (n = 9 neurons with pregabalin from 4 rats; n = 8 neurons without pregabalin from four rats) and paclitaxel-treated rats (n = 8 neurons with pregabalin from four rats; n = 9 neurons without pregabalin from four rats). *p < 0.05 compared with the respective baseline control (one-way ANOVA followed by Dunnett's post hoc test).
neurons) or vehicle-treated rats (n = 12 neurons) ( Fig. 5a and b). These findings indicate that a2d-1-bound NMDARs are responsible for the paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn.
a2d-1-bound NMDARs are crucial for paclitaxel-induced activation of NMDARs at primary afferent terminals To determine whether a2d-1-bound NMDARs contribute to the paclitaxel-induced increase in NMDAR activity at primary afferent terminals, we examined the effect of a2d-1Tat peptide on EPSCs of lamina II neurons monosynaptically evoked from the dorsal root. In spinal cord slices from paclitaxel-treated rats (n = 9 neurons), treatment with 1 lM a2d-1Tat peptide for 30-60 min completely reversed the increased amplitude of evoked EPSCs to the level found in vehicle-treated rats ( Fig. 6a-d) . Subsequent bath application of AP5 had no effect on the amplitude of evoked EPSCs in neurons from paclitaxel-treated rats. Also, a2d-1Tat peptide did not affect the amplitude of evoked EPSCs in neurons from vehicle-treated rats (n = 10 neurons). In contrast, treatment with Tat-fused control peptide (1 lM for 30-60 min) did not significantly alter the amplitude of evoked EPSCs of lamina II neurons from paclitaxel-treated rats (n = 12 neurons) or vehicle-treated rats (n = 9 neurons) ( Fig. 6a-d) . In control peptide-incubated neurons from paclitaxel-treated rats, bath application of AP5 returned the amplitude of evoked EPSCs to the level observed in vehicletreated rats.
In addition, treatment with a2d-1Tat peptide, but not Tatfused control peptide, fully reversed the reduction in the baseline PPR of evoked EPSCs in neurons from paclitaxeltreated rats (n = 9 neurons in each group; Fig. 6e ). Bath application of AP5 reversed the reduced PPR in control peptide-treated neurons from paclitaxel-treated rats but had no effect on the PPR in a2d-1Tat peptide-treated neurons from paclitaxel-treated rats. In spinal cord slices from vehicle-treated rats, treatment with a2d-1Tat peptide (n = 10 neurons) or control peptide (n = 9 neurons) had no effect on the baseline PPR of evoked EPSCs (Fig. 6f) . These results indicate that a2d-1-bound NMDARs are critically involved in paclitaxel-induced activation of NMDARs at primary afferent terminals in the spinal dorsal horn.
a2d-1 ablation prevents paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn To further validate the critical role of a2d-1 in paclitaxelinduced tonic activation of presynaptic NMDARs in the spinal dorsal horn, we performed electrophysiological recordings in spinal cord slices from wild-type (WT) and a2d-1 knockout (KO) mice that had been treated with paclitaxel. The baseline frequency, but not the amplitude, of mEPSCs was significantly greater in lamina II neurons from WT mice (n = 11 neurons) than in those from a2d-1 KO mice (n = 16 neurons) (4.92 AE 0.48 Hz vs. 3.13 AE 0.46 Hz, p = 0.018). Also, bath application of AP5 normalized the paclitaxel-induced increase in the frequency of mEPSCs in WT mice but had no effect in a2d-1 KO mice (Fig. 7a-c) .
The amplitude of monosynaptic EPSCs of spinal lamina II neurons evoked from the dorsal root in paclitaxel-treated WT mice (n = 13 neurons) was significantly higher than that in paclitaxel-treated a2d-1 KO mice (n = 11 neurons) (518.68 AE 15.06 pA vs. 412.14 AE 21.82 pA, p < 0.016). Bath application of AP5 normalized the increased baseline amplitude of evoked EPSCs in WT mice but had no effect in a2d-1 KO mice ( Fig. 8a and b) . Furthermore, the PPR of evoked EPSCs was significantly lower in neurons from paclitaxel-treated WT mice (n = 13 neurons) than in those from paclitaxel-treated a2d-1 KO mice (n = 10 neurons) (0.60 AE 0.05 vs. 0.80 AE 0.07, p = 0.029). Bath application of AP5 restored the baseline PPR that had been decreased by paclitaxel in WT mice but had no effect in paclitaxel-treated a2d-1 KO mice ( Fig. 8c and d) . These data provide unequivocal evidence of the obligatory role of a2d-1 in paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn.
Inhibiting a2d-1 or disrupting the a2d-1-NMDAR interaction at the spinal cord level reverses paclitaxelinduced pain hypersensitivity Blocking NMDARs at the spinal cord level can rapidly reverse pain hypersensitivity induced by chemotherapeutic agents (Xie et al. , 2017 . We next determined specifically whether a2d-1-bound NMDARs at the spinal cord level contribute to paclitaxel-induced neuropathic pain. Rats were injected intraperitoneally with 2 mg/kg of paclitaxel every 2 days for a total of four injections. The behavioral Representative recording traces and cumulative plots (a) and box-andwhisker plots (b) show the effect of bath application of 50 lM 2-Amino-5-phosphonopentanoic acid (AP5) on the frequency and amplitude of mEPSCs of lamina II neurons from paclitaxel-treated rats, Neurons were treated with 1 lM a2d-1Tat peptide (n = 10 neurons from 5 rats) or 1 lM control peptide (n = 11 neurons from 5 rats). (c and d) Original recording traces and cumulative plots (c) and box-and-whisker plots (d) show the effect of bath application of AP5 on the frequency and amplitude of mEPSCs of lamina II neurons from vehicle-treated rats. Neurons were treated with 1 lM a2d-1Tat peptide (n = 11 neurons from five rats) or 1 lM control peptide (n = 12 neurons from five rats). *p < 0.05 compared with the respective baseline control (one-way ANOVA followed by Dunnett's post hoc test).
# p < 0.05 compared with the baseline level in the group treated with control peptide (one-way ANOVA followed by Tukey's post hoc test).
tests were conducted 14 days after treatment with paclitaxel. Paclitaxel-treated rats had lower withdrawal thresholds in response to application of a tactile stimulus (von Frey filaments), a noxious pressure stimulus, and a noxious heat stimulus to the hindpaw than did vehicle-treated rats, indicating the presence of pain hypersensitivity. Intrathecal injection of 5 lg pregabalin readily reversed tactile allodynia and mechanical and thermal hyperalgesia in paclitaxeltreated rats (n = 8 rats per group, Fig. 9a-c) . Similarly, intrathecal injection of 1 lg a2d-1Tat peptide, but not 1 lg control peptide, markedly attenuated the pain hypersensitivity induced by paclitaxel (n = 8 rats per group; Fig. 9a-c) . wild-type (WT, n = 11 neurons from five mice) and a2d-1 knockout (KO, n = 16 neurons from five mice) mice treated with paclitaxel. *p < 0.05 compared with the respective baseline control (one-way ANOVA followed by Dunnett's post hoc test). # p < 0.05 compared with the baseline level in WT mice (one-way ANOVA followed by Tukey's post hoc test). Original recording traces (a) and box-and-whisker plots (b) show the effect of bath application of 50 lM 2-Amino-5-phosphonopentanoic acid (AP5) on evoked monosynaptic excitatory postsynaptic currents (EPSCs) of lamina II neurons from paclitaxel-treated rats. Neurons were treated with 1 lM a2d-1Tat peptide (n = 9 neurons from four rats) or 1 lM control peptide (n = 12 neurons from four rats). (c and d).
Representative recording traces (c) and box-and-whisker plots (d) show the effect of bath application of 50 lM AP5 on evoked monosynaptic EPSCs of lamina II neurons from vehicle-treated rats. Neurons were treated with 1 lM a2d-1Tat peptide (n = 10 neurons from four rats) or 1 lM control peptide (n = 9 neurons from four rats). In b and d (right panels), values are normalized to their respective baselines. (e and f). Original recording traces (e) and box-and-whisker plots (f) shows the effect of bath application of 50 lM AP5 on the paired-pulse ratio (PPR) of lamina II neurons treated with a2d-1Tat peptide or control peptide from vehicle-treated (n = 10 neurons with a2d-1Tat peptide from four rats; n = 9 neurons with control peptide from four rats) and paclitaxel-treated rats (n = 9 neurons with a2d-1Tat peptide from four rats; n = 9 neurons with control peptide from four rats). *p < 0.05 compared with the respective baseline control (oneway ANOVA followed by Dunnett's post hoc test).
# p < 0.05 compared with the baseline level in the group treated with control peptide (oneway ANOVA followed by Tukey's post hoc test).
These data suggest that a2d-1 and a2d-1-bound NMDARs at the spinal cord level play a prominent role in paclitaxelinduced neuropathic pain.
a2d-1 ablation attenuates the development of pain hypersensitivity caused by paclitaxel treatment Next, we used a2d-1 KO mice to confirm the contribution of a2d-1 to the development of pain hypersensitivity after paclitaxel treatment (2 mg/kg, 4 injections on days 1, 3, 5, and 7). Systemic treatment with paclitaxel in WT mice induced tactile allodynia and heat and cold hyperalgesia, which began after the second paclitaxel injection and lasted for at least 10 days after the last injection (n = 8 mice per group; Fig. 10a-c) . The withdrawal thresholds in response to von Frey filaments and heat/cold stimuli at baseline (before paclitaxel treatment) did not differ significantly between WT and a2d-1 KO mice. However, the degree of tactile allodynia and heat/cold hyperalgesia induced by paclitaxel was profoundly attenuated in a2d-1 KO mice (n = 8 mice per group; Fig. 10a -c). Treatment with vehicle had no effects on the tactile and thermal withdrawal thresholds in either WT or a2d-1 KO mice (n = 8 mice per group). These results provide substantial evidence that a2d-1 contributes to the development of paclitaxel-induced neuropathic pain.
Discussion
The most striking finding of our study is that a2d-1 is essential for paclitaxel-induced tonic activation of presynaptic NMDARs in the spinal dorsal horn. We have shown that postsynaptic NMDAR activity in the spinal dorsal horn is not affected by paclitaxel treatment (Chen et al. 2014c ). In our recording condition, the postsynaptic NMDARs were minimally open because the cell was voltage-clamped at -60 mV and recorded in the presence of 1.2 mM Mg 2+ in the extracellular solution. Presynaptic NMDARs are emerging as important regulators of neuronal signaling in processes such as long-term potentiation (Zhou et al. 2010; Park et al. 2014) and spinal synaptic plasticity in various chronic pain conditions (Li et al. 2016; Xie et al. 2016 Xie et al. , 2017 Chen et al. 2018) . a2d-1 is expressed in the DRG and spinal cord laminae I and II (Newton et al. 2001; Cole et al. 2005; Taylor and Garrido 2008) , and the obligatory NMDAR subunit GluN1 is present at primary Original recording traces (c) and box-and-whisker plots (d) shows the effect of bath application of AP5 on the paired-pulse ratio (PPR) of lamina II neurons from WT (n = 13 neurons from five mice) and a2d-1 KO (n = 10 neurons from five mice) mice treated with paclitaxel. *p < 0.05 compared with the respective baseline control (one-way ANOVA followed by Dunnett's post hoc test).
# p < 0.05 compared with the baseline level in WT mice (one-way ANOVA followed by Tukey's post hoc test).
afferent nerve terminals near the active zone in the rat spinal dorsal horn (Liu et al. 1994) . However, the role of a2d-1 in regulating presynaptic NMDARs has been generally overlooked until recently. We showed in this study that inhibiting a2d-1 trafficking with pregabalin or disrupting the a2d-1-NMDAR interaction with a2d-1Tat peptide completely normalized paclitaxel-induced, NMDAR-mediated, increases in synaptic glutamate release to dorsal horn neurons. Also, inhibiting a2d-1 or disrupting the a2d-1-NMDAR interaction reversed the paclitaxel-induced increase in evoked glutamate release from primary afferent terminals. Furthermore, our results from a2d-1 KO mice indicate that presynaptic NMDAR activation in paclitaxel-treated animals fully depends on a2d-1. Paclitaxel is mostly accumulated in the DRG and peripheral nerves upon systemic administration (Cavaletti et al. 2000) , which may explain its preferential toxic effect on primary afferent nerves. As a whole, our study provides unambiguous evidence that paclitaxel-induced activation of presynaptic NMDARs is predominantly mediated by a2d-1-bound NMDARs.
Our study provides new evidence about the molecular mechanism through which paclitaxel-induced a2d-1 upregulation leads to activation of presynaptic NMDARs in the spinal dorsal horn. Under physiological conditions, presynaptic NMDARs in the spinal cord are not functionally active. However, these receptors become tonically activated by endogenous glutamate in painful conditions caused by paclitaxel, bortezomib, and calcineurin inhibitors (Li et al. 2016; Xie et al. 2016 Xie et al. , 2017 Chen et al. 2018) . We found that paclitaxel treatment caused a2d-1 up-regulation in the DRG and the dorsal spinal cord, which is consistent with other reports (Matsumoto et al. 2006; Xiao et al. 2007; Gauchan et al. 2009 ). Because a2d-1 is a highly glycosylated protein involved in surface trafficking (Tetreault et al. 2016) , the paclitaxel-induced excess of a2d-1 protein at primary afferent terminals may promote its interaction with NMDARs and facilitate synaptic expression of a2d-1-NMDAR complexes. In support of this notion, we found that paclitaxel increased the association between a2d-1 and NMDARs in the spinal cord and the prevalence of a2d-1-bound NMDARs in the spinal cord synaptosomes. It should be noted that dorsal spinal cord synaptosomes do not necessarily represent the central terminals of primary afferents, and this synaptosomal preparation can underestimate the changes in the protein complexes at the presynaptic terminals of primary afferents. Paclitaxel-induced presynaptic NMDAR activation involves primarily GluN2A-containing NMDARs . Although these receptors are normally blocked by Mg 2+ at negative membrane potentials, their association with a2d-1 can markedly reduce the voltage-dependent Mg 2+ block of NMDARs . This distinct effect of a2d-1 on GluN2A-containing NMDARs also likely accounts for the paclitaxel-induced emergence of functionally active NMDARs at primary afferent terminals. Thus, the switch from a2d-1-free to a2d-1-bound NMDARs constitutes a crucially important molecular mechanism for tonic activation of presynaptic NMDARs, which potentiates glutamate release from primary afferent nerves through Ca 2+ influx. We showed that neither pregabalin nor a2d-1Tat peptide had any effect on synaptic glutamate release to spinal dorsal horn neurons in rats without paclitaxel-induced neuropathic pain. The finding that a2d-1 interacts with NMDARs and plays a key role in activating presynaptic NMDARs under chronic pain conditions could explain why gabapentinoids reduce the release of neurotransmitters including calcitonin gene-related peptide, substance P, and glutamate in the spinal cord under persistent painful, but not normal, conditions (Fehrenbacher et al. 2003; Chen et al. 2018) . In a heterologous expression system, gabapentinoids reduce NMDAR activity only when a2d-1 is co-expressed , indicating that a2d-1-bound NMDARs are the predominant NMDARs involved in the effect of gabapentinoids. The role of a2d-1 in the activation of presynaptic NMDARs caused by paclitaxel treatment is likely independent of VACCs, because mEPSCs of dorsal horn neurons were recorded in the presence of tetrodotoxin (a voltage-activated sodium channel blocker), which prevents neuronal depolarization and VACC activation. Also, a2d-1Tat peptide specifically targets the Cterminus of a2d-1, which is required for the a2d-1-NMDAR interaction, whereas the VWA domain (near the N-terminus) of a2d-1 mediates the interaction between a2d-1 and VACCs (Canti et al. 2005; Hoppa et al. 2012) . Furthermore, the a2d-1Tat peptide and gabapentinoids have no effect on VACC activity or on the interaction between a2d-1 and the VACC a1 subunit. In addition, a2d-1 physically interacts with NMDARs in HEK293 cells, which do not express VACC a1 subunits .
Our findings suggest that paclitaxel treatment increases both the expression and synaptic localization of NMDARs at the spinal cord level. However, our electrophysiological data from treatment with pregabalin and a2d-1Tat peptide as well as a2d-1 KO mice indicate that a2d-1 is critically involved in the paclitaxel treatment-induced increase in presynaptic NMDAR activity at the spinal cord level. Although it has been reported that a2d-1 may interact with thrombospondins to promote synaptogenesis (Eroglu et al. 2009 ), a recent study showed that the a2d-1-thrombospondin interaction is very weak and that no a2d-1-thrombospondin interaction Fig. 10 a2d-1 contributes to paclitaxel-induced pain hypersensitivity. (a-c). Time course of changes in the paw withdrawal thresholds tested with von Frey filaments (a), a heat stimulus (b), and a cold stimulus (c) in wild-type (WT) and a2d-1 knockout (KO) mice treated with paclitaxel (n = 8 mice per group). BL, baseline before paclitaxel treatment. The four paclitaxel injections are indicated by the arrows. Data are expressed as means AE SEM. *p < 0.05, compared with respective baseline (BL) value before paclitaxel treatment (one-way ANOVA followed by Dunnett's post hoc test). # p < 0.05 compared with the corresponding value at the same time point in WT mice (two-way ANOVA followed by Tukey's post hoc test).
takes place on the membrane surface (Lana et al. 2016) . In this study, we showed that the paclitaxel-induced increase in the mEPSC frequency of dorsal horn neurons was rapidly reversed by blocking NMDARs, indicating that augmented glutamatergic input is mediated by NMDARs, but not by increased synaptogenesis.
Our study provides new evidence for the pivotal role of a2d-1-bound NMDARs at the spinal cord level in the development of chronic pain after paclitaxel treatment. We showed that inhibiting a2d-1 or disrupting the a2d-1-NMDAR interaction at the spinal cord level readily reversed the pain hypersensitivity caused by paclitaxel treatment. In addition, the development of paclitaxel-induced pain hypersensitivity was profoundly blunted in a2d-1 KO mice. Although blocking NMDARs at the spinal cord level effectively reverses persistent pain caused by paclitaxel and bortezomib (Xie et al. , 2017 , conventional NMDAR antagonists, such as ketamine, often produce intolerable adverse effects because they inhibit normal NMDAR function. It is conceivable that gabapentinoids or compounds specifically targeting the a2d-1-NMDAR interaction site may have more favorable therapeutic profiles than general NMDAR antagonists.
In summary, our study reveals that a switch from a2d-1-free to a2d-1-bound NMDARs serves as a key molecular mechanism by which presynaptic NMDARs are activated in chemotherapy-induced pain and that this switch also mediates the therapeutic effect of gabapentinoids. Chemotherapy induces dominance of a2d-1-bound NMDARs at primary afferent terminals, causing long-lasting increases in glutamatergic nociceptive input to spinal dorsal horn neurons and thereby maintaining chronic pain. This new information not only extends our understanding of the fundamental molecular mechanism underlying chemotherapy-induced neuropathic pain but also provides a basis for the rational use of gabapentinoids. Targeting the a2d-1-NMDAR interaction site may be a new strategy for specifically inhibiting abnormally increased NMDAR activity (without interfering with normal, a2d-1-free NMDARs) to treat this painful condition in cancer patients and survivors.
